Navigation Links
Mass. General team develops potentially safer general anesthetic
Date:7/22/2009

A team of Massachusetts General Hospital (MGH) physicians has developed a new general anesthetic that may be safer for critically ill patients. In the August issue of Anesthesiology, they describe preclinical studies of the drug called MOC-etomidate a chemically altered version of an exiting anesthetic which does not cause the sudden drop in blood pressure seen with most anesthetics or prolonged suppression of adrenal gland activity, a problem with the original version of the drug.

"We have shown that making a version of etomidate that is broken down very quickly in the body reduces the duration of adrenal suppression while retaining etomidate's benefit of keeping blood pressure much more stable than other anesthetics do," says Douglas Raines, MD, of the MGH Department of Anesthesia, Critical Care and Pain Medicine, who led the study.

Almost all general anethetic agents reduce blood pressure immediately after they are administered, which is not a problem for young and healthy patients but can have serious consequences for those who are elderly, critically ill or suffering from blood loss. For such patients, etomidate is often used to induce anesthesia, but since adrenal suppression sets in quickly and can last for several hours to days, other agents are used to maintain anesthesia during a procedure, requiring very careful monitoring to avoid dangerous blood pressure drops.

In their search for a safer version of etomidate, the research team mimicked the chemical structure of other "soft analogue" drugs derivatives of parent drugs designed to be rapidly metabolized by adding a molecule that causes the drug to broken down by natural enzymes soon after producing its effects. Experiments in tadpoles and rats showed that the new agent, MOC-etomidate, quickly produced anesthesia from which the animals recovered rapidly after administration ceased. The rat study verified that MOC-etomidate had little effect on blood pressure levels and no effect on adrenal activity, even when administered at twice the dosage required to produce anesthesia.

The researchers note that, since the study only examined the effect of a single dose of MOC-etomidate, their next step will be to study continuous infusion of the drug. Additional data must be gathered from animal studies before testing the agent in human patients is feasible. "If all goes well, we expect that we could give a large dose of MOC-etomidate to induce anesthesia and then run a continuous infusion to maintain anesthesia without reducing blood pressure in even very sick patients," Raines says. "We also anticipate that patients will wake more quickly and with less sedation after surgery and anesthesia."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Mass. General-based research center will investigate why immune system fails to control hepatitis C
2. Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform
3. Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies
4. Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
5. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
6. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
7. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
8. LCA Congratulates Nominee For Surgeon General
9. U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families
10. Pelosi Statement on Appointment of Dr. Regina Benjamin as Surgeon General of the United States
11. Obama Taps Alabama Doctor to Be Surgeon General
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston ... Center, is currently offering complimentary consultations and financing for orthodontics for a limited ... bite irregularities and learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day ...
(Date:1/16/2017)... MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the ... , This year’s influenza shot seems to be having no effect on keeping ... at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... , ... San Francisco dentist, Dr. Ben Amini , the founder at ... is capable of taking digital impressions of teeth and gums. Conventional bite impressions have ... restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are ...
(Date:1/15/2017)... ... 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version ... for purchase. , The 2017 edition has wide jaws that will accommodate nails up ... as well as diabetics. This handle is reinforced for extra strength when pressing down on ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology: